Article Text

Download PDFPDF
Journal club
Pneumonia and inhaled corticosteroids in COPD
  1. Avais Jabbar
  1. Correspondence to Dr Avais Jabbar, Department of General Medicine, Northampton General Hospital NHS Trust, Northampton NN1 5BD, UK; ajabbar1{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Combination treatment with inhaled corticosteroids and long-acting β2-agonists decreases exacerbations and improves quality of life in patients with COPD; however; a potential concern is an increased risk of pneumonia. Although the TORCH and INSPIRE studies have shown the risk of pneumonia to increase with fluticasone/salmeterol versus placebo and tiotropium, there has been no direct comparison of fixed combinations of inhaled corticosteroids/long-acting β2-agonists.

The PATHOS study compared …

View Full Text